Discussion Of Correlation Of The Genotype And Anti-virus Therapeutics Of Hepatitis B Virus

HBV is a kind of mis-classification double stranded DNA virus. This virus is one of the most detriment. It is a major causative agent of acute and chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. About 50-70 percent of the chronic hepatitis B infective patient have been athletic virus replication and lives inflammation. Infective natural course of disease is really long and keep up about 30-50 years. Type B of hepatitis have become the cosmopolitism disease that seriously threaten the health of human and it is also one of the contagious that is the most widespread popular and the most serious harm contagious disease. HBV is been infected all over the world. These cosmopolitan distribution are different everywhere. At present the genotyping were divided eight genotyps:A,B,C,D,E,F,G and H, according to the heterogeneity of the whole gene order greater than or equal 8 percent or the heterogeneity of the S gene of HBV genome greater than or equal 4 percent. The different HBV genotyps effect the progression of disease and tumover of chronic patient of HBV and the express of the maker of HBV and the therapeutic of the antiviral drug. HBV genotyps have been the most important guidance significance to estimate the therapeutic drugs and choose therapeutic regimen. In this study, we are mainly to find HBV genotype epidemiology . To discuss the correlation of different hepatitis B virus genotyp with lamivudine or interferon . Our attention is to guide the clinical therapy. We use PCR-fluorescence detection hepatitis B virus genotype of 90 cases. The main experiment object concluding, the positive of HBV DNA(>5×102copies), the positive of HBeAg and abnormal of ALT. Patients with different genotype HBV were treated with lamivudine and interforn for 6 months. The changes ofHBV DNA, HBeAg and ALT were detected. PCR-fluorescence detection for hepatitis B virus genotyp use the tecnology Taqman-fluorescence. This technology use a amplicon and duplicate bands genotyp specificity fluorescent probe. The single band probe detects HBV genotype C.FAM fluorescein act as the reporter group. Another band probe detects HBV B genotyp. VIC fluorescein act as reporter group. The experimental data in the fluorescent quantitation PCR were monitored. It is very simple to decide the HBV genotyp and apply usually equipment. This way is good on the accuration. This way compared with the genotype of nucleotide sequence . The results of two ways are the same percent 100.The result of the study demonstrate that the 33 cases(36.6%)were HBV B genotype,48 case(53.3%) were HBV C genotype ,eight cases(8.9%)were HBV BC genotype and one case(1.1%) was non-BC genotype of 90 cases. Patients of HBV B genotype were treated with interferon for 6 months. Genotype B with HBV DNA levels turned to be negative( HBV DNA<5×102copies ) was 73.9%, HBeAg seroconversion of genotype B was 78.3% and ALT common was 73.9%. Patients were treated for lamivudine for 6 months . Genotype B with HBV DNA levels turned to be negative( HBV DNA<5×102copies ) was 30.0%, HBeAg seroconversion of genotype B was 40.0% and ALT common was 70.0%. Patients of HBV B genotype were treated with interforn and lamivudine. Genotype B with HBV DNA levels turned to be negative and HBeAg seroconversion of genotype B were compared (p〈0.05). ALT were compared (p〉0.05). Patients of HBV C genotype were treated with lamivudine for 6 months. Genotype C with HBV DNA levels turned to be negative( HBV DNA<5×102copies ) was 89.5%, HBeAg seroconversion of genotype B was 84.2% and ALT common was92.1%. Patients were treated with interforn for 6 months. Genotype C with HBV DNA levels turned to be negative( HBV DNA<5×102copies ) was 30.0%, HBeAg seroconversion of genotype B was 40.0% and ALT common was50.0%. Patients of HBV C genotype were treated with interforn and lamivudine. Genotype C with HBV DNA levels turned to be negative and HBeAg seroconversion of genotype B and ALT were compared (p〈0.05). Because HBV BC genotyp and non-HBV BC genotyp is very few, this study has not statistics. The result hints that HBV genotypes in hepatitis patients of HBVDNA positive(HBV DNA>5×102copies),HBeAg positive and ALT abnormal of 90 cases have HBV B genotype, HBV C genotype, HBV BC genotype and HBV non-BC genotype. Genotype C is the advantage genotype, and has the same as the reports from abroad and south. The interforn treated HBV B genotype were better than HBV C genotype. The lamivudine treated HBV C genotype were better than HBV B genotype. So HBV genotype has important significance to clinical dignostitic and treatment and so on.